Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Under a five-year deal, ZymoGenetics (ZGEN) granted Serono (SWX:SEO; SRA) access to a portfolio of genes and proteins for evaluation, screening and licensing for a total of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury